We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Waters Sets New Standards for High Resolution Performance and Speed With Xevo MRT Mass Spectrometer

Protein structure.
Credit: iStock.
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 3 minutes

72nd ASMS Conference on Mass Spectrometry and Allied Topics – Waters Corporation (NYSE: WAT) unveiled the Xevo™ MRT, its highest-performing benchtop mass spectrometer (MS), setting new standards for delivering high resolution and speed, critical for large population and epidemiology-type studies. It builds on the innovative technology pioneered by the Waters SELECT SERIES™ MRT MS. The new Xevo MRT MS combines the raw power and resolution speed of multi-reflecting time-of-flight (MRT) and hybrid quadrupole time-of-flight (QTof) technologies within a flexible benchtop platform.

"Understanding complex diseases requires analysis of thousands of samples from large human cohorts to provide statistically valid studies. This puts increased pressure on drug discovery scientists to deliver high-quality data in shorter run times," said Dr. Udit Batra, CEO and President of Waters Corporation. "The Xevo MRT mass spectrometer is a next generation QTof built from the ground up to address this unmet need, delivering high resolution and speed without compromising analytical performance. Its multi-reflecting time-of-flight design enables simultaneous high sensitivity, high resolution, and speed in a small footprint, accelerating time-to-results and ensuring high-quality experimental outcomes."

The Xevo MRT system delivers a class-leadingiii 100,000 full width half maximum (FWHM) resolution at 100 Hz MS/MS scan speed and <500 parts per billion (ppb) mass accuracy. This enables deeper probing of biologically relevant concentrations with high levels of mass accuracy, independent of acquisition rate.

"A range of mass spec approaches are available for metabolomic, lipidomic, and metabolite identification studies, yet all require compromises to be made - either in data quality or analytical efficiency," said Professor Perdita Barran, Chair of Mass Spectroscopy in the University of Manchester (UK) Department of Chemistry and Director of the Michael Barber Centre for Collaborative Mass Spectrometry at the Manchester Institute of Biotechnology. "The Xevo MRT MS is impressive technology capable of higher sample throughput combined with extremely high precision, which can significantly advance target validation and phenotyping studies. The increase in scan speed and data quality are critical as it can allow us to run more samples in less time without compromising confidence in our data and we are very excited by how this is allowing us to accelerate the development of a diagnostic test for Parkinson's Disease."

The innovative multi-reflecting time-of-flight design of the Xevo MRT MS offers scientists the power to work at maximum resolution with high sensitivity and fast data acquisition rates. This helps ensure confident identification of analytes across a range of samples and complex matrices and generate comprehensive and highly accurate mass data for scientific interpretation.

Waters offers complete workflows for metabolomic, lipidomic, and metabolite identification for the Xevo MRT MS, alongside Waters high throughput ACQUITY™ UPLC™ Systems and UPLC Column chemistries and waters_connect™ Software for data acquisition, processing, and reporting. The system supports universal data-sharing via mzML file formats with third-party informatics software, including popular applications from Mass Analytica™ such as its MARS, Lipostar2, and MassMetaSite software offerings.

The Waters Xevo MRT MS is orderable today for shipment in the second half of 2024.